Key facts
- It has raised $317.6M; the latest was Early Stage VC ($17.6M) in Oct 2024.
- Notable investors include Service Provider Capital, Olive Tree Capital, Catalio Capital Management, Spur Capital Partners, Ascent Equity Partners — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Affini-T
- ·The full record, as it builds
Funding rounds
No funding rounds for Affini-T are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Affini-T
Operator of a precision immunotherapy company intended to target core oncogenic driver mutations to develop potentially curative therapies for patients with solid tumors. The company specializes in identifying T-cell receptors against targets like KRAS and TP53 that are fundamental to tumor biology and leverages synthetic biology, enabling medical researchers to deliver therapies for patients with pancreatic, colorectal, and lung cancers.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2020
- Employees
- 88
- Website
- affinittx.com/
- Ownership
- Privately Held (backing)
Affini-T doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Affini-T shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Affini-T in its N-PORT filings yet. We sweep new filings monthly.